Status:
COMPLETED
Targeted Fluorescence Imaging in AMD
Lead Sponsor:
University Medical Center Groningen
Conditions:
Age-Related Macular Degeneration
NAMD
Eligibility:
All Genders
60+ years
Phase:
PHASE1
Brief Summary
Rationale: To track performance of intravitreal distribution of anti-VEGF-A (Bevazicumab-800CW) and provide information about neovascularization and inflammation in Age-Related Macular Degeneration (...
Eligibility Criteria
Inclusion
- Patients with either naïve wet AMD or wet AMD receiving standard care of anti-VEGF therapy
- Aged \>60 years old
- Optional: Patients already included in fluorescence study which involves Bevacizumab-800CW
Exclusion
- Eye pathology interfering with retinal imaging;
- Patients with psychological diseases or medical issues who are not able to sign informed consent form;
- Concurrent uncontrolled medical conditions;
- Received a different investigational drug within 30 days prior to the dose of bevacizumab-800CW;
- History of infusion reactions to bevacizumab or other monoclonal antibody.
Key Trial Info
Start Date :
October 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2024
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT05262244
Start Date
October 28 2022
End Date
March 30 2024
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University medical center Groningen (UMCG)
Groningen, Provincie Groningen, Netherlands, 9713 GZ